121 related articles for article (PubMed ID: 35946538)
1. Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report.
Zhang F; Li X; Liu H; Liu R; Zhou Z; Zhang Y; Chen J; Tian Y; Pan C; Meng Q; Liu Y
Anticancer Drugs; 2022 Oct; 33(9):975-978. PubMed ID: 35946538
[TBL] [Abstract][Full Text] [Related]
2. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
Luchini C; Grant RC; Scarpa A; Gallinger S
Gut; 2021 Oct; 70(10):1809-1811. PubMed ID: 33468535
[No Abstract] [Full Text] [Related]
4. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer.
Tsang ES; Walker EJ; Carnevale J; Fisher GA; Ko AH
Immunotherapy; 2021 Oct; 13(15):1249-1254. PubMed ID: 34338034
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy Combined with Chemotherapy in Relapse Metaplastic Breast Cancer.
Chen L; Meng Z; Zhou Z; Li X; Zhao L; Jia Z; Chen J; Tian Y; Meng Q; Liu Y
Onco Targets Ther; 2023; 16():885-890. PubMed ID: 37927329
[TBL] [Abstract][Full Text] [Related]
6. Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Ye Y; Zheng S
Front Immunol; 2021; 12():785400. PubMed ID: 34880877
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Li S; Peng Y; Li J; Guo F; Yi C; Cao D
Front Immunol; 2020; 11():1127. PubMed ID: 32636837
[No Abstract] [Full Text] [Related]
9. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Overman M; Javle M; Davis RE; Vats P; Kumar-Sinha C; Xiao L; Mettu NB; Parra ER; Benson AB; Lopez CD; Munugalavadla V; Patel P; Tao L; Neelapu S; Maitra A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114502
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract][Full Text] [Related]
12. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions.
Lawlor RT; Mattiolo P; Mafficini A; Hong SM; Piredda ML; Taormina SV; Malleo G; Marchegiani G; Pea A; Salvia R; Kryklyva V; Shin JI; Brosens LA; Milella M; Scarpa A; Luchini C
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206554
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
[TBL] [Abstract][Full Text] [Related]
17. Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population.
Sini MC; Doro MG; Frogheri L; Zinellu A; Paliogiannis P; Porcu A; Scognamillo F; Delogu D; Santeufemia DA; Persico I; Palomba G; Maestrale GB; Cossu A; Palmieri G
J Transl Med; 2024 Jan; 22(1):108. PubMed ID: 38280995
[TBL] [Abstract][Full Text] [Related]
18. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
20. A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report.
Han MY; Borazanci E
J Gastrointest Oncol; 2023 Feb; 14(1):458-462. PubMed ID: 36915432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]